急性冠状动脉综合征抗血小板降阶治疗策略的研究进展

袁祖贻; 肖懿慧

doi:10.13201/j.issn.1001-1439.2022.10.001

急性冠状动脉综合征抗血小板降阶治疗策略的研究进展

袁祖贻^1, ,,
肖懿慧¹

- 西安交通大学第一附属医院心血管内科(西安，710061)

详细信息

通讯作者: 袁祖贻，E-mail: zuyiyuan@mail.xjtu.edu.cn

中图分类号: R541.4

收稿日期: 2022-09-14

刊出日期: 2022-10-13

Research progress of antiplatelet de-escalation strategy in acute coronary syndrome

YUAN Zuyi^1, ,,
XIAO Yihui¹

- Department of Cardiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China

More Information

Corresponding author: YUAN Zuyi, E-mail: zuyiyuan@mail.xjtu.edu.cn

Received Date: 14 September 2022

Publish Date: 13 October 2022

摘要

摘要: 双联抗血小板治疗是指南推荐的急性冠状动脉综合征患者的标准治疗。然而随着危险因素的良好控制、新型P2Y₁₂受体拮抗剂以及新一代药物支架的应用，血栓风险已明显下降，而出血风险日益受关注，如何实现缺血与出血的平衡成为近年来临床实践的热点与焦点。大量临床研究从抗血小板治疗的时程、剂量、强度、种类探索了降阶治疗的可行性，为急性冠状动脉综合征患者的个体化抗血小板治疗策略提供了证据和支持，相信随着未来越来越多循证证据的出现，最优化的抗血小板治疗将不断更新，以期实现患者缺血和出血的最大净获益。
- 急性冠状动脉综合征 /
- 抗血小板治疗 /
- 降阶治疗
Abstract: Dual antiplatelet therapy is the standard treatment for patients with acute coronary syndrome(ACS) recommended by guidelines. However, with the control of risk factors, the application of new P2Y₁₂ receptor antagonists and the second-generation drug stents, the risk of thrombosis has been significantly reduced, while the risk of bleeding has increased day by day. How to achieve the balance between ischemia and bleeding has become the hot spot of clinical practice in recent years. A large number of clinical studies had explored the feasibility of antiplatelet de-escalation therapy from duration, dose, strength and species, and provided evidence for individualized antiplatelet therapy in patients with ACS. We believe that the largest net benefit of ischemia and hemorrhage can be realized in the future with more and more research evidences and the optimized application of antiplatelet therapy.
- acute coronary syndrome /
- antiplatelet /
- de-escalation

HTML全文

参考文献(23)

[1]	Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association[J]. Circulation, 2017, 135(10): e146-e603.
[2]	韩雅玲. 冠心病抗血小板治疗的新潮流: 降阶治疗[J]. 中华心血管病杂志, 2019, 10(47): 759-761. https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL202206016.htm
[3]	Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2007, 357(20): 2001-2015. doi: 10.1056/NEJMoa0706482
[4]	Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO): a randomised double-blind study[J]. Lancet, 2010, 375(9711): 283-293. doi: 10.1016/S0140-6736(09)62191-7
[5]	Palmerini T, Reggiani LB, Riva DD, et al. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting[J]. J Am Coll Cardiol, 2017, 69(16): 2011-2022. doi: 10.1016/j.jacc.2017.02.029
[6]	Bonaca MP, Bhatt DL, Cohen M, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction[J]. N Engl J Med, 2015, 372(19): 1791-1800. doi: 10.1056/NEJMoa1500857
[7]	Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54(PEGASUS-TIMI 54) trial[J]. Am Heart J, 2014, 167(4): 437-444. e5. doi: 10.1016/j.ahj.2013.12.020
[8]	Costa F, Vranckx P, Leonardi S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6-or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY(Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)trial[J]. Eur Heart J, 2015, 36(20): 1242-1251. doi: 10.1093/eurheartj/ehv038
[9]	Gilard M, Barragan P, Noryani AAL, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial[J]. J Am Coll Cardiol, 2015, 65(8): 777-786. doi: 10.1016/j.jacc.2014.11.008
[10]	Han Y, Xu B, Xu K, et al. Six versus12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized sub-study of the I-LOVE-IT 2 trial[J]. Circ Cardiovasc Interv, 2016, 9(2): e003145.
[11]	Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction(DAPT-STEMI): randomised, multi-centre, non-inferiority trial[J]. BMJ, 2018, 363: k3793.
[12]	Plemerini T, Stone GW. optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence[J]. Eur Heart J, 2016, 37(4): 353-364. doi: 10.1093/eurheartj/ehv712
[13]	Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial[J]. JAMA, 2019, 321(24): 2414-2427. doi: 10.1001/jama.2019.8145
[14]	Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)[J]. Eur Heart J, 2018, 39(3): 213-260. doi: 10.1093/eurheartj/ehx419
[15]	Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial[J]. JAMA, 2019, 321(24): 2428-2437. doi: 10.1001/jama.2019.8146
[16]	Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study[J]. Am Heart J, 2016: 125-134.
[17]	Kim BK, Hong SJ, Cho YH, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: the TICO Randomized Clinical Trial[J]. JAMA, 2020, 323(23): 2407-2416. doi: 10.1001/jama.2020.7580
[18]	Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multi-centre, open-label, randomised superiority trial[J]. Lancet, 2018, 392(10151): 940-949. doi: 10.1016/S0140-6736(18)31858-0
[19]	Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study[J]. Eur Heart J, 2017, 38(41): 3070-3078. doi: 10.1093/eurheartj/ehx175
[20]	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention(TROPICAL-ACS): a randomised, open-label, multi-centre trial[J]. Lancet, 2017, 390(10104): 1747-1757.
[21]	Thomas OB, Paul WJ, Jurjan CS, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI(POPULAR)Genetics study[J]. Am Heart J, 2014, 168(1): 16-22. doi: 10.1016/j.ahj.2014.03.006
[22]	Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stablised patients with acute myocardial infarction undergoing percutaneous coronary intervention(TALOS-AMI): an investigator-initiated, open-label, multi-centre, non-inferiority, randomised trial[J]. Lancet, 2021, 398: 1305-1316. doi: 10.1016/S0140-6736(21)01445-8
[23]	Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome(HOST-REDUCE-POLYTECH-ACS): an open-label, multi-centre, non-inferiority randomised trial[J]. Lancet, 2020, 396(10257): 1079-1089. doi: 10.1016/S0140-6736(20)31791-8